61 results about "Pemphigus" patented technology

Disclosed are compositions useful for treating Alzheimer's disease, atherosclerosis, arteriosclerosis, osteoarthritis and other degenerative joint diseases, Huntington's chorea, Parkinson's disease, optic atrophy, retinitis pigmentosa, macular degeneration, muscular dystrophy, aging-associated degenerative processes, asthma, dermatitis, laminitis, pemphigoid, pemphigus, reactive airway disease (e.g., COPD, IAD), inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis), multiple sclerosis, rheumatoid arthritis, periodontal disease, systemic lupus erythematosus, sarcoidosis, psoriasis, type I diabetes, ischemia-reperfusion injury, chronic inflammatory diseases, geriatric wasting, cancer cachexia, cachexia associated with chronic inflammation, sick feeling syndrome, and other inflammatory and / or degenerative diseases, disorders, conditions, and processes in humans and other animals. In one embodiment, the compositions include at least 4 of the following: a MMP1 inhibitor, a MMP2 inhibitor, a MMP3 inhibitor, a MMP7 inhibitor, a MMP9 inhibitor, an ADAMTS-4 inhibitor, a MMP13 inhibitor, and a MMP14 inhibitor. In another embodiment, the compositions include a curcuminoid, a polymethoxylated flavone, a catechin, and a boswellic acid.

Compositions of azathioprine oral suspensions are disclosed. Disclosed azathioprine oral suspensions may be used to administer azathioprine to subjects such as children and geriatric patients that may have difficulty in swallowing solid dosage forms. The disclosed azathioprine oral suspension may be used for treating autoimmune diseases such as rheumatoid arthritis, pemphigus, Behcet's disease, autoimmune hepatitis, and inflammatory bowel disease, among others. According to an embodiment, an aqueous or non-aqueous vehicle may be used for azathioprine oral suspension. According to a different embodiment, sugar free azathioprine oral suspension may also be produced.

The present invention provides a monoclonal antibody having a pathogenic activity that can induce pemphigus lesion, a peptide specifically recognized by the monoclonal antibody and useful as a therapeutic drug for pemphigus autoimmune disease, etc. As anti-mouse Dsg3 antibody-producing cells are present in the splenocytes of pemphigus vulgaris mouse model constructed by using autoantigen knockout mouse, cell fusion was conducted with the splenocytes of said mouse model and mouse myeloma cells using polyethyleneglycol, hybridomas were constructed, and monoclonal antibodies against Dsg3 were constructed. Among them, a monoclonal antibody having a pathological activity that can induce pemphigus lesions was screened, the base sequence and amino acid sequence in its variable region (heavy chain, light chain) was determined, and the specific epitope part was identified.

This invention relates to compositions and methods for the use of anti-autoimmune reagents that specifically bind to anti-desmoglein antibodies, which are responsible for both pemphigus vulgaris and pemphigus foliaceus. In addition, the invention relates to methods and compositions for inhibiting the expression or function of a variable region of an anti-desmoglein (anti-Dsg) pathogenic autoantibody.

The invention specifically relates to application of interleukin 35 to preparation of drugs used for treating autoimmune dermatoses, a therapeutic drug, and an IL-35-Fc fusion protein, belonging to the field of biochemical drugs. The objective of the invention is to provide a novel effective approach for treatment of autoimmune dermatoses. According to a technical scheme in the invention, application of interleukin 35 to preparation of drugs for treating psoriasis is provided. Results show that IL-35 has good treatment effect, small toxic and side effect and simple operation in treatment of psoriasis, so a novel option is provided for treatment of autoimmune dermatoses like psoriasis, chorionitis and pemphigus.

The present disclosure provides methods of treating with a BTK inhibitor a blistering disease, in particular pemphigus vulgaris or pemphigus folliaceous in a mammal, use of a BTK inhibitor as a replacement therapy for corticosteroid therapy for diseases treatable with a corticosteroid, such as autoimmune or inflammatory disease and in particular where corticosteroids are used as first or second line therapy, and pharmaceutical formulations comprising the same.

The present invention provides isolated peptides relating to the autoimmune disease Pemphigus vulgaris. The peptides relating to Pemphigus vulgaris are self epitopes derived from human pathogens which are implicated in the aetiology and remissions of the disease. Pharmaceutical preparations for tolerizing and / or immunizing individuals are provided as well as methods relating thereto. Methods are provided for identifying other self and non-self epitopes involved in human autoimmune disease and similar pharmaceutical preparations and methods of use for these epitopes are also provided.

Perp is shown to mediate stratified epithelial development in vivo. Perp localizes specifically to desmosomes, adhesion junctions important for tissue integrity. In some embodiments of the invention, detection of autoantibodies specific for perp find use in the diagnosis of pemphigus. In other embodiments, agent that upregulate or mimic perp function are useful in treatment of such blistering diseases. In another embodiment, agents that inhibit perp function are useful in treating and preventing cancer.

The present invention relates to methods of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cell. In particular, diseases or disorders including contact dermatitis, drug induced delayed type cutaneous allergic reactions, toxic epidermal necrolysis, cutaneous T cell lymphoma, bullous pemphigoid, alopecia aereata, vitiligo, acne rosacea, prurigo nodularis, and herpes simplex virus, or combination thereof will benefit from the administration of an IL-31 antagonist. The invention also includes methods of predicting a therapeutically responsive patient population.

The invention discloses an application of single nucleotide polymorphic rs3888722 in screening pemphigus foliaceus patients. The technical scheme of the invention relates to an application of a substance for detecting the polymorphism or genotype of rs3888722 in human genome in preparing a product for screening pemphigus foliaceus patients and an application of a substance for detecting the polymorphism or genotype of rs3888722 in human genome in preparing a product for detecting the single nucleotide polymorphism related to pemphigus foliaceus. The substance for detecting the polymorphism or genotype of rs3888722 can be combined with other substances (including the substance for detecting other single nucleotide polymorphism or genotype related to pemphigus foliaceus) to prepare a product for screening pemphigus foliaceus patients.

This invention relates to compositions and methods for the use of anti-autoimmune reagents that specifically bind to anti-desmoglein antibodies, which are responsible for both pemphigus vulgaris and pemphigus foliaceus. In addition, the invention relates to methods and compositions for inhibiting the expression or function of a variable region of an anti-desmoglein (anti-Dsg) pathogenic autoantibody.

The present invention provides for the identification of an antigen surrogate to the native antigens for the autoimmune disease pemphigus vulgaris. Ligands are discovered using large random peptoid or cyclic peptoid libraries that are screened against known antibodies to autoimmune diseases. The ligands may be useful as drugs in the treatment of such diseases and can also be used in combination with the concomitant removal of T-cells associated with autoimmune disorders.

The present invention provides for the identification of an antigen surrogate to the native antigens for the autoimmune disease pemphigus vulgaris. Ligands are discovered using large random peptoid or cyclic peptoid libraries that are screened against known antibodies to autoimmune diseases. The ligands may be useful as drugs in the treatment of such diseases and can also be used in combination with the concomitant removal of T-cells associated with autoimmune disorders.

The invention belongs to the technical field of traditional Chinese medicines and particularly relates to a traditional Chinese medicine composition formula for preventing and treating allergic dermatitis. The traditional Chinese medicine composition formula comprises raw materials in parts by weight as follows: 10-20 parts of raw astragalus membranaceus, 10-20 parts of prepared tuber fleeceflower roots, 10-20 parts of officinal magnolia bark, 10-20 parts of fineleaf schizonepeta herbs, 10-20 parts of divaricate saposhnikovia roots, 10-20 parts of slough, 10-20 parts of common ducksmeat herbs, 10-20 parts of virgate wormwood herbs, 10-20 parts of belvedere fruits, 10-20 parts of densefruit pittany root-bark, 2-10 parts of golden thread, 3-10 parts of largetrifoliolious bugbane rhizomes and 2-10 parts of liquorice. The traditional Chinese medicine composition formula is reasonable, raw materials used in the formula have a wide source and are low in cost, the traditional Chinese medicine composition has a reliable curative effect and a mild drug property, does not have toxic or side effects, is convenient to take or carry after being prepared in the form of powder, capsules, decoction or pills according to the requirement of Chinese pharmacopoeia (2010), has a satisfactory curative effect in treatment of various allergic reaction skin diseases such as urticaria, neurodermatitis, pruritus cutanea, contact allergic dermatitis, pemphigus and the like and is popular with patients and doctors.

The invention discloses a traditional Chinese medicine for treating pemphigus erythematosus. The traditional Chinese medicine comprises the following Chinese herbal medicines: Jackinthepulpit tuber, herb of tufted bracket plant, flower of Japanese kerria, marshy betony, herb of hispid arthraxon, Mongolian peach, bulb of Fritillaria taipaiensis P.Y.Li, root of giant timber bamboo, snakegourd seed, herb of Peking spleenwort, Chinese usnea, root of younghusband jerusalemsage, fruit of lingnan artocarpus, juice of Japanese white birch., Artemisia halodendron Turcz., root of Japanese avens, nacre, chlorite schist and rhizoma pinelliae pedatisectae. The traditional Chinese medicine takes the pure natural Chinese herbal medicines as raw materials, treats both symptoms and root causes, has definite curative effects, does not have toxic or side effects and enables the disease not easy to recur.

The invention relates to a pharmaceutical composition comprising lysozyme, dextranase and an essential oil of a plant belonging to the family Myrtaceae. The composition is preferably formulated, together with other ingredients, as a mouthwash.The invention also relates to a method for the prevention, treatment and follow-up of pathologies of the oral cavity of infectious, inflammatory, degenerative or autoimmune origin, the method comprising the administration of the composition of the invention to a patient affected by one or more of such pathologies, which are preferably selected in the group consisting of: gingivitis, periodontitis, aphthous stomatitis, herpetic stomatitis, prosthetic stomatitis, recurrent aphthosis, xerostomia, xerostomia due to Sjogren's syndrome, burning mouth syndrome (BMS), oral candidiasis, inflammatory dermatoses such as oral lichen planus, autoimmune disorders of the mucous membranes such as mucous membrane pemphigoid (MMP), graft-versus-host disease, white tongue, migratory glossitis, desquamative gingivitis due to oral lichen planus, herpes and combinations thereof.

This invention describes a method of preventing and treating inflammatory skin diseases by topical application of aurin tricarboxylic acid and its derivatives. Such diseases are characterized by immune attack, especially involving aberrant complement activation. The diseases include, but are not limited to, androgenetic alopecia (baldness), seborrheic dermatitis / dandruff, allergic dermatitis, primary cicatricial alopecia, pemphigus, psoriasis, discoid lupus erythematosis and dermatitus herpetiformis.

The invention provides a scar pemphigus local treatment auxiliary device for an ophthalmology and otorhinolaryngology department, and belongs to the technical field of medical instruments. The problems that the process of treating an intraoral affected part in a mouth rinsing mode is tedious, the situation that clear water or gargle is mistakenly swallowed by a patient exists during mouth rinsing, and the clear water or the gargle in contact with the intraoral affected part is likely to carry bacteria of the affected part and causes secondary harm to the patient after being mistakenly swallowed are solved. The scar pemphigus local treatment auxiliary device for the ophthalmology and otorhinolaryngology department comprises a handle, a first placement cavity is defined in the handle, a box body is fixedly connected to the upper end of the handle, a second placement cavity is defined in the box body, a guide rod is arranged at the left end of the box body, a power mechanism for driving the auxiliary device to operate is arranged in the first placement cavity, and a liquid storage mechanism for storing the clear water and the gargle is arranged in the second placement cavity. The scar pemphigus local treatment auxiliary device for the ophthalmology and otorhinolaryngology department is more convenient and safer to use and better in gargle effect.

The present invention provides isolated peptides relating to the autoimmune diseases pemphigus vulgaris and multiple sclerosis. The peptides relating to pemphigus vulgaris are self epitopes and those relating to multiple sclerosis are foreign antigens derived from human pathogens which are implicated in the aetiology and remissions of the disease. Pharmaceutical preparations for tolerizing and / or immunizing individuals are provided as well as methods relating thereto. Methods are provided for identifying other self and non-self epitopes involved in human autoimmune disease and similar pharmaceutical preparations and methods of use for these epitopes are also provided.

Disclosed is a composition for the inhibition of transplant rejection and the prevention and treatment of skin diseases, comprising a cordyceps mycellia extract as an active ingredient. The cordyceps mycellia extract significantly suppresses the production of antibodies to transplants without side effects, such as weight change. Based on natural material, the composition is non-toxic and harmless to the human body and thus can be used as an immunosuppressant for organ transplantation. Also, it stops oozing from sores and is useful in the prevention and treatment of skin diseases, including atopy, allergic reactions, decubitus ulcers, pemphigus and smallpox.

This invention describes a method of preventing and treating inflammatory skin diseases by topical application of aurin tricarboxylic acid and its derivatives. Such diseases are characterized by immune attack, especially involving aberrant complement activation. The diseases include, but are not limited to, androgenetic alopecia (baldness), seborrheic dermatitis / dandruff, allergic dermatitis, primary cicatricial alopecia, pemphigus, psoriasis, discoid lupus erythematosis, and dermatitus herpetiformis.

The invention discloses a preparation method for a traditional Chinese medicine preparation treating pemphigus. The traditional Chinese medicine preparation comprises the following bulk drugs: tip of licorice root, realgar, common dysosmatis rhizome and root, herb of denseleaf crazyweed, galla chinensis, donkey-hide glue, rhizoma atractylodis macrocephalae, radix aucklandiae, radix polygalae, radix asteris, fructus trichosanthis, radix peucedani, root of woolly tylophora, semen sterculiae lychnophorae, elecampane inula root, lablab purpureus, dace, waternut herb, caragana sinica root, semen cuscutae, borneolum syntheticum, radix sophorae flavescentis, giant typhonium tuber, pericarpium zanthoxyli and corydalis boweri. The dosage form of the traditional Chinese medicine preparation is a granula, and the concrete preparation process comprises: mixing, grinding, immersing, boiling, separating out a first decoction, and performing the same process to separate out a secondary decoction, mixing the decoctions, performing centrifugal separation and drying, adding cane sugar and beta-cyclodextrin, and preparing the granula. Compared with the prior art, the traditional Chinese medicine preparation has the efficacy of clearing heat and detoxifying, regulating qi and blood, promoting qi circulation and moistening lung, nourishing stomach and fortifying spleen, dispelling dampness and relieving pain, and relieving nidus, and is relatively strong in pertinency.

The present invention relates to a composition for use in the prevention of the rejection of skin tissue, comprising an effective amount of a peptide comprising an epitope of an antigen selected from the group of the polypeptides type XVII collagen, VII collagen, integrin alpha 6, integrin beta 4, chains of laminin, chains of laminin 322, type IV collagen, plectin, plakoglobin, bullous pemphigoid antigen 1, periplakin, envoplakin, desmoglein 1, desmoglein 3, a desmocollin and human bullous pemphigoid antigen 2 (hBPAG2) wherein said epitope induces immunological tolerance against its underlying polypeptide, and / or a nucleic acid for expressing a peptide comprising an epitope of said antigen as well as a gene therapy based on the composition, in the context of autoimmune blistering diseases, such as bullous pemphigoid or genetic skin diseases such as epidermolysisbullosa.

The invention relates to a derivative of alpha-amino phosphonic acid containing saccharide groups, a preparation method and the medical application thereof, in particular to a compound which is represented by formula I and can adjust the functions of the immune system, a stereoisomer thereof and application of medical composition containing the compound and the stereisomer in preventing or treating autoimmune diseases, such as chronic nephritis, multiple sclerosis, psoriasis, systemic lupus erythematosus, rheumatoid arthritis, insulin-dependent diabetes, chronic and toxic thyroiditis, myasthenia gravis, ankylosing spondylitis, pemphigus and the like as well as organ transplantation and allergic diseases and the like or application as tool medicine for studying diseases related to the function of the immune system and / or the functional disorder of the immune system.

The invention relates to blood poison eliminating capsules, which is prepared from the following raw materials: antelope horn, scorpio, centipede, unprepared rehmannia root, sinkiang arnebia root, glabrous greenbrier rhizome and talc powder. A preparation method of the blood poison eliminating capsules comprises the following steps of: smashing antelope horn, scorpio, centipede and a half of the glabrous greenbrier rhizome into fine powder and mixing uniformly for later use; decocting unprepared rehmannia root, sinkiang arnebia root and the remaining glabrous greenbrier rhizome respectively, extracting, combining decoction liquids, filtering and concentrating the filtrate into thick paste for later use; and mixing the thick paste with the fine powder, drying, smashing, mixing uniformly, adding the talc powder, mixing uniformly and filling into capsules. The blood poison eliminating capsules have a simple preparation process, low cost, high medicament bioavailability, high stability, remarkable curative effect and no remarkable toxic or side effect, are scientifically prepared from Chinese medicinal herbs serving as raw materials, and have the effects of cooling the blood and removing the toxic materials, are mainly used for treating blood poisons such as psoriasis, erythroderma, systemic lupus erythematosus, dermatomyositis and pemphigus at acute stages, severe dermatitis medicamentosa, and the like. A more convenient and quicker Chinese traditional treatment mode is provided for the clinical treatment of skin diseases.

The present invention concerns developing a remedy for treating pemphigus by administering a CD40L antagonist to patients with pemphigus such as pemphigus vulgaris or pemphigus foliaceus, and a preventive agent for preventing the development of pemphigus by preventively administering a CD40L antagonist. Antagonists such as an anti-CD40L antibody that inhibit the interaction between a CD40L mediating the contact-dependent helper effector function on the T cell surface and a CD40 receptor on the antigen-presenting cell surface, were effective as a remedy and a preventive agent for pemphigus.

The invention relates to a traditional Chinese medicine composition for treating skin diseases such as acne and herpes zoster. The traditional Chinese medicine composition comprises the following ingredients in parts by weight: 20-30 parts of radix rehmanniae, 10-15 parts of radix saposhnikoviae, 10-15 parts of roasted tribulus terrestris, 20-30 parts of roasted jasmine, 15-20 parts of Japanese honeysuckle, 20-25 parts of fructus forsythiae, 10-15 parts of ligusticum wallichii, 10-15 parts of flos chrysanthemi indici, 10-25 parts of roasted coptis root, 10-25 parts of radix scrophulariae, 10-15 parts of liquorice and 20-25 parts of roasted radix scutellariae. The composition is prepared by uniformly mixing, grinding and sieving with a 120-mesh sieve. The composition has the advantages thatthe treatment time is short; the curing speed is high; the diseases can be cured by administration of the composition for 4-5 times; and the composition has no toxic or side effects, and can be usedfor treating the acne, verruca plana, eczema, rubella, urticaria and pemphigus.

The invention belongs to the technical field of traditional Chinese medicine, and specifically relates to a traditional Chinese medicine composition formula for preventing and treating allergic skin diseases. The traditional Chinese medicine composition formula of the present invention consists of the following raw materials in parts by weight: 10-20 parts of raw astragalus, 10-20 parts of prepared polygonum multiflorum, 10-20 parts of Magnolia officinalis, 10-20 parts of Schizonepeta, and 10-20 parts of Fangfeng 10-20 parts of cicada slough, 10-20 parts of duckweed, 10-20 parts of wormwood, 10-20 parts of kochia chinensis, 10-20 parts of white bark, 2-10 parts of coptis, 3-10 parts of cohosh 2-10 servings of raw licorice. The traditional Chinese medicine composition of the present invention has a reasonable formula, wide sources of raw materials used in the formula, low cost, reliable curative effect, mild medicinal properties, and no toxic or side effects. It is a powder, capsule, decoction or pill prepared in accordance with the requirements of the Chinese Pharmacopoeia 2010 Edition. Easy to take or carry. It is used to treat various allergic (allergic) skin diseases such as urticaria, neurodermatitis, pruritus, contact allergic dermatitis and pemphigus. It has achieved satisfactory results and is well received by patients and doctors.

The invention discloses an ELISA (enzyme-linked immuno sorbent assay) kit for detecting a human BP180 IgG (immunoglobulin G) antibody and application of the ELISA kit. The kit contains a BP180 microporous band, and the BP180 microporous band is respectively coated with polypeptides as shown in SEQ ID NO. 1-29 or a mixture of the polypeptides as shown in SEQ ID NO. 1-29. Preferably, the kit also contains standard serum 1 and 2, an enzyme-labeled antibody, a diluent, a reaction buffer solution, a cleaning buffer solution, an enzyme matrix solution and a stop solution. According to the invention, a plurality of antigen polypeptides are used for replacing a long-fragment complete protein as a coating protein of ELISA, so that a large amount of cost is saved while antigen epitopes recognized by an antibody are fully guaranteed, and compared with NC16a recombinant protein, the sensitivity is higher. According to the invention, the human BP180 IgG antibody is detected by using an ELISA method, and compared with an existing immunoblotting method, the ELISA method is easier to be applied to clinical diagnosis of bullous pemphigus and BP180 type mucous membrane pemphigus.